Possible Multiple Myeloma Dedifferentiation Following Thalidomide Therapy: A Report of Four Cases

References

• Tosi, P. and Cavo, M. (2002) "Thalidomide in multiple myeloma: state of art", Haematologica, 87, 233–235.
   PubMed Web of Science ®Google Scholar
• Anderson, K.C. (2001) "Novel biologically based therapies for myeloma", Cancer Journal, 13(Suppl), 19 — 23.
   Google Scholar
• Singhal, S., Metha, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New England Journal of Medicine, 341, 1565 — 1571.
   PubMed Web of Science ®Google Scholar
• Kneller, A., Raanani, P., Hardan, I., Avigor, A., Levi, I., Berkowicz, M., et al. (2000) "Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug", British Journal of Haematology, 108, 391— 393.
   Google Scholar
• Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. and Malm, C. (2000) "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma", British Journal of Haematology, 109, 89–96.
   Google Scholar
• Pith, M., Baraldi, A., Pietrasanta, D., Allione, B., Depaoli, L., Salvi, F., et al. (2000) "Low-dose of thalidomide in the treatment of refractory myeloma", Haematologica, 85, 111 —112.
   PubMed Web of Science ®Google Scholar
• Hus, M., Dmoszynska, A., Soroka-Woitaszko, M., Jawniak, D., Legiec, W., Ciepnuch, H., et al. (2001) "Thalidomide treatment of resistant or relapsed multiple myeloma patients". Haematologica, 86, 404–408.
   PubMed Web of Science ®Google Scholar
• Tosi, P., Ronconi, S., Zamagni, E., Cellini, C., Grafone, T., Cangini, D., et al. (2001) "Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation", Haematologica, 86, 409–413.
   Google Scholar
• Tosi, P., Zamagni, E., Cellini, C., Ronconi, S., Patriarca, F., Ballerini, F., et al. (2002) "Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma", Haematologica, 87, 408–414.
   Google Scholar
• Singhal, S. and Metha, J. (2001) "Thalidomide in cancer: potential use and limitations", Biodrugs, 15, 163–172.
   PubMed Web of Science ®Google Scholar
• Marriot, J.B., Muller, G. and Dalgleish, A.G. (1999) "Thalidomide as an emerging immunotherapeutic agent", Immunology Today, 20, 538–543.
   PubMedGoogle Scholar
• D'Amato, R.J., Loughnan, M.S., Flynn, E. and Folkman, J. (1994) "Thalidomide is an inhibitor of angiogenesis", Proceedings of National Academy of Sciences USA, 91, 4082–4085.
   PubMed Web of Science ®Google Scholar
• Haslett, P.A., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide costimulates primary human T lymphocytes, prefer-entially inducing proliferation, cytokine production and cytotoxic responses in the CD8 + subset", Journal of Experimental Medicine, 187, 1885–1892.
   PubMed Web of Science ®Google Scholar
• Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., et al. (2001) "Thalidomide and immunomodulatory deriva-tives augment natural killer cell cytotoxicity in multiple myeloma", Blood, 98, 210–216.
   Google Scholar
• Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) "Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes", Journal of Experi-mental Medicine, 173, 699–703.
   Google Scholar
• Petrucci, M.T., Ricciardi, M.R. and Gregorj, C. (2000) "Thalido-mide effects on apoptosis in multiple myeloma: ex vivo and in vitro study", Blood, 96\(Suppl 1), 366 [abstract].
   Google Scholar
• Pope, B., Brown, R.D., Gibson, J., Petersen, A., Wiley, J. and Joshua, D.E. (1997) "The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state", Leukemia and Lymphoma, 117, 83–91.
   Google Scholar
• Sanal, S.M., Yaylaci, M., Mangold, K.A. and Pantazis, C.G. (1996) "Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferantion", Cancer, 77, 1298–1302.
   Google Scholar
• Avigdor, A., Raanani, P., Levi, I., Hardan, I. and Ben-Bassat, I. (2001) "Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma", Leukemia and Lymphoma, 42, 683–687.
   Google Scholar
• Alegre, A., Granda, A., Martinez-Chamorro, C., Diaz-Mediavilla, J., Martinez, R., Garcia-Larana, J., et al. (2002) "Different patterns of relapse after peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry", Haematologica, 87, 609–614.
   PubMed Web of Science ®Google Scholar